Repository logo

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

dc.contributor.authorKeith, Paul K.
dc.contributor.authorCowan, Juthaporn
dc.contributor.authorKanani, Amin
dc.contributor.authorKim, Harold
dc.contributor.authorLacuesta, Gina
dc.contributor.authorLee, Jason K.
dc.contributor.authorChen, Jie
dc.contributor.authorPark, Michelle
dc.contributor.authorGladiator, André
dc.date.accessioned2023-06-27T03:27:49Z
dc.date.available2023-06-27T03:27:49Z
dc.date.issued2023-06-23
dc.date.updated2023-06-27T03:27:50Z
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2023 Jun 23;19(1):54
dc.identifier.urihttps://doi.org/10.1186/s13223-023-00805-3
dc.identifier.urihttps://doi.org/10.20381/ruor-29301
dc.identifier.urihttp://hdl.handle.net/10393/45095
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleCorrection: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
13223_2023_Article_805.pdf
Size:
859.45 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: